Peptide and Peptidomimetic Inhibitors Targeting the Interaction of Collapsin Response Mediator Protein 2 with the N-Type Calcium Channel for Pain Relief

Overview

Journal ACS Pharmacol Transl Sci

Publisher American Chemical Society

Specialty Biochemistry

Date 2024 Jul 18

PMID 39022365

Authors

Samantha Perez-Miller

Kimberly Gomez

Rajesh Khanna

Affiliations

Soon will be listed here.

Abstract

Ion channels serve pleiotropic functions. Often found in complexes, their activities and functions are sculpted by auxiliary proteins. We discovered that collapsin response mediator protein 2 (CRMP2) is a binding partner and regulator of the N-type voltage-gated calcium channel (Ca2.2), a genetically validated contributor to chronic pain. Herein, we trace the discovery of a new peptidomimetic modulator of this interaction, starting from the identification and development of CBD3, a CRMP2-derived Ca binding domain peptide. CBD3 uncouples CRMP2-Ca2.2 binding to decrease Ca2.2 surface localization and calcium currents. These changes occur at presynaptic sites of nociceptive neurons and indeed, CBD3 ameliorates chronic pain in preclinical models. In pursuit of a CBD3 peptidomimetic, we exploited a unique approach to identify a dipeptide with low conformational flexibility and high solvent accessibility that anchors binding to Ca2.2. From a pharmacophore screen, we obtained CBD3063, a small-molecule that recapitulated CBD3's activity, reversing nociceptive behaviors in rodents of both sexes without sensory, affective, or cognitive effects. By disrupting the CRMP2-Ca2.2 interaction, CBD3063 exerts these effects indirectly through modulating Ca2.2 trafficking, supporting CRMP2 as an auxiliary subunit of Ca2.2. The parent peptide CBD3 was also found by us and others to have neuroprotective properties at postsynaptic sites, through -methyl-d-aspartate receptor and plasmalemmal Na/Ca exchanger 3, potentially acting as an auxiliary subunit for these pathways as well. Our new compound is poised to address several open questions regarding CRMP2's role in regulating the Ca2.2 pathways to treat pain with the potential added benefit of neuroprotection.

References

Kowara R, Chen Q, Milliken M, Chakravarthy B . Calpain-mediated truncation of dihydropyrimidinase-like 3 protein (DPYSL3) in response to NMDA and H2O2 toxicity. J Neurochem. 2005; 95(2):466-74. DOI: 10.1111/j.1471-4159.2005.03383.x. View

Quinn C, Chen E, Kinjo T, Kelly G, Bell A, Elliott R . TUC-4b, a novel TUC family variant, regulates neurite outgrowth and associates with vesicles in the growth cone. J Neurosci. 2003; 23(7):2815-23. PMC: 6742060. View

Brittain J, Duarte D, Wilson S, Zhu W, Ballard C, Johnson P . Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex. Nat Med. 2011; 17(7):822-9. PMC: 3219927. DOI: 10.1038/nm.2345. View

Jiang Y, Andrade A, Lipscombe D . Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel CaV2.2 pre-mRNA. Mol Pain. 2013; 9:67. PMC: 3916075. DOI: 10.1186/1744-8069-9-67. View

Shahlaie K, Gurkoff G, Lyeth B, Muizelaar J, Berman R . Neuroprotective effects of SNX-185 in an in vitro model of TBI with a second insult. Restor Neurol Neurosci. 2012; 31(2):141-53. DOI: 10.3233/RNN-120243. View

Feng Z, Doering C, Winkfein R, Beedle A, Spafford J, Zamponi G . Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J Biol Chem. 2003; 278(22):20171-8. DOI: 10.1074/jbc.M300581200. View

Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N . CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci. 2001; 4(8):781-2. DOI: 10.1038/90476. View

Moutal A, Ji Y, Bellampalli S, Khanna R . Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury. Mol Brain. 2020; 13(1):97. PMC: 7310452. DOI: 10.1186/s13041-020-00633-1. View

Ji Y, Hu Y, Ren J, Khanna R, Yao Y, Chen Y . CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Aβ-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway. Chem Biol Interact. 2019; 305:28-39. DOI: 10.1016/j.cbi.2019.03.005. View

10.

Zhang Z, Ottens A, Sadasivan S, Kobeissy F, Fang T, Hayes R . Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma. 2007; 24(3):460-72. DOI: 10.1089/neu.2006.0078. View

11.

Koes D, Camacho C . ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res. 2012; 40(Web Server issue):W409-14. PMC: 3394271. DOI: 10.1093/nar/gks378. View

12.

Goshima Y, Nakamura F, STRITTMATTER P, Strittmatter S . Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature. 1995; 376(6540):509-14. DOI: 10.1038/376509a0. View

13.

Rajamani D, Thiel S, Vajda S, Camacho C . Anchor residues in protein-protein interactions. Proc Natl Acad Sci U S A. 2004; 101(31):11287-92. PMC: 509196. DOI: 10.1073/pnas.0401942101. View

14.

Finnerup N, Otto M, McQuay H, Jensen T, Sindrup S . Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005; 118(3):289-305. DOI: 10.1016/j.pain.2005.08.013. View

15.

Gomez K, Ran D, Madura C, Moutal A, Khanna R . Non-SUMOylated CRMP2 decreases Na1.7 currents via the endocytic proteins Numb, Nedd4-2 and Eps15. Mol Brain. 2021; 14(1):20. PMC: 7819318. DOI: 10.1186/s13041-020-00714-1. View

16.

Suto T, Eisenach J, Hayashida K . Peripheral nerve injury and gabapentin, but not their combination, impair attentional behavior via direct effects on noradrenergic signaling in the brain. Pain. 2014; 155(10):1935-42. PMC: 4197111. DOI: 10.1016/j.pain.2014.05.014. View

17.

Braden K, Stratton H, Salvemini D, Khanna R . Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces and prevents pain chronification in a mouse model of oxaliplatin-induced neuropathic pain. Neurobiol Pain. 2022; 11:100082. PMC: 8733339. DOI: 10.1016/j.ynpai.2021.100082. View

18.

Vivas O, Castro H, Arenas I, Elias-Vinas D, Garcia D . PIP₂ hydrolysis is responsible for voltage independent inhibition of CaV2.2 channels in sympathetic neurons. Biochem Biophys Res Commun. 2013; 432(2):275-80. DOI: 10.1016/j.bbrc.2013.01.117. View

19.

Pajouhesh H, Feng Z, Zhang L, Pajouhesh H, Jiang X, Hendricson A . Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2012; 22(12):4153-8. DOI: 10.1016/j.bmcl.2012.04.054. View

20.

Piekarz A, Due M, Khanna M, Wang B, Ripsch M, Wang R . CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain. 2012; 8:54. PMC: 3502107. DOI: 10.1186/1744-8069-8-54. View